Compounds > tegafur
Page last updated: 2024-11-04

tegafur and Vomiting

tegafur has been researched along with Vomiting in 47 studies

Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Research Excerpts

ExcerptRelevanceReference
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."9.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."9.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia."9.08[The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. ( Hayashida, S; Hirasawa, T; Mitsui, H; Nasu, T; Shinohara, Y; Uchiyama, K, 1995)
"Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma."9.08Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996)
" In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)."7.69Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997)
"Palonosetron was not superior to granisetron in combination antiemetic therapy."5.43Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016)
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."5.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."5.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"The purpose of this study was to evaluate the efficacy, assessed as response rate, and toxicity of UFT (Tegafur-Uracil) in combination with oxaliplatin as first-line treatment of advanced colorectal cancer (CRC)."5.11Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. ( Antón-Aparicio, L; Aparicio, J; Constela, M; Dorta, FJ; Feliu, J; Fonseca, E; García-Girón, C; Gonzalez-Baron, M; Lomas, M; Vicent, JM, 2004)
"Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia."5.08[The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer]. ( Hayashida, S; Hirasawa, T; Mitsui, H; Nasu, T; Shinohara, Y; Uchiyama, K, 1995)
"Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma."5.08Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996)
" In a previous study, the authors demonstrated that the combination of uracil and tegafur (UFT) with leucovorin (LV) was active and well tolerated in patients with advanced colorectal carcinoma (ACC)."3.69Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group. ( Colmenarejo, A; de Castro, J; de la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Fernández, Y; García Girón, C; González Barón, M; Jalón, JI, 1997)
"A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study."3.66Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983)
"Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown."2.90Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019)
"This phase I trial of preoperative S-1 in combination with oxaliplatin and radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis revealed that the recommended dose of oxaliplatin was 60 mg/m(2) weekly."2.80A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015)
" Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity."2.76[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011)
" Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle."2.75Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010)
"Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period."2.68[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995)
"The main toxicity was diarrhea and oral mucositis."2.68Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma. ( Cheong, SK; Kim, JS; Kim, YH; Lee, JD; Park, JS; Shin, SW, 1996)
" Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day."2.68Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996)
"Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC."1.46Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017)
"Palonosetron was not superior to granisetron in combination antiemetic therapy."1.43Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016)
" With regard to adverse events, the rates of nausea (p<0."1.42[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015)
" Severe adverse events were observed in 22 patients (91."1.42Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015)
"In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed."1.40Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014)
"Among the 65 patients with advanced esophageal cancer, 27 had no history of prior chemotherapy and the other 38 had ever received postoperative adjuvant chemotherapy before."1.35[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. ( Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008)
"Nine advanced gastric cancer patients were given 17 courses of cisplatin administrations by means of a 24-hour intravenous infusion at a dose of 100 mg/m2."1.28[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin]. ( Aoki, Y; Horiuchi, Y; Kamikawa, R; Kyokane, K; Miwa, Y; Nagai, H; Ninomiya, E; Noro, T; Suga, S; Yasue, K, 1990)
"Diarrhea was the dose-limiting toxic effect and occurred more often in patients with abnormal pretreatment liver function."1.27Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"Forty cases with head and neck cancer were entered in the trial, of which 37 were perfectly evaluable."1.27[A phase II study of Futraful suppository in head and neck cancer]. ( Furuta, S; Hanada, T; Kamachi, S; Katsuta, K; Matsumura, M; Matsunaga, S; Moriyama, I; Nobori, T; Ohyama, M; Uchizono, A, 1988)
"FD-1, a new anticancer drug, is a fluorinated pyrimidine derivative that has shown less acute toxicity than 5-FU and FT-207, and higher antitumor activity than FT-207 in Ehrlich carcinoma, S-180, AH-130, Yoshida sarcoma, and Walker 256."1.26Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1). ( Taguchi, T, 1980)

Research

Studies (47)

TimeframeStudies, this research(%)All Research%
pre-19907 (14.89)18.7374
1990's20 (42.55)18.2507
2000's2 (4.26)29.6817
2010's17 (36.17)24.3611
2020's1 (2.13)2.80

Authors

AuthorsStudies
Kobayashi, S1
Ueno, M2
Ogawa, G1
Fukutomi, A2
Ikeda, M3
Okusaka, T4
Sato, T3
Ito, Y2
Kadota, T1
Ioka, T2
Sugimori, K2
Sata, N1
Nakamori, S2
Shimizu, K3
Mizuno, N2
Ishii, H3
Furuse, J4
Morizane, C2
Mizusawa, J1
Katayama, H1
Ozaka, M1
Okano, N2
Hara, H1
Yanagimoto, H1
Wada, K2
Tobimatsu, K1
Yane, K1
Yamaguchi, H2
Asagi, A1
Yukisawa, S1
Kojima, Y1
Kawabe, K2
Kawamoto, Y1
Sugimoto, R1
Iwai, T1
Nakamura, K1
Miyakawa, H1
Yamashita, T1
Hosokawa, A1
Kato, N1
Shioji, K1
Nakagohri, T1
Kamata, K1
Fang, M1
Song, T1
Liang, X1
Lv, S1
Li, J1
Xu, H1
Luo, L1
Jia, Y1
Hamada, C1
Ikari, T1
Isayama, H1
Nakai, Y1
Imai, S1
Okamura, S1
Wang, F1
Fan, QX2
Wang, HH1
Han, DM1
Song, NS1
Lu, H1
Yamada, Y1
Koizumi, W2
Nishikawa, K1
Gotoh, M1
Fuse, N1
Sugimoto, N1
Nishina, T1
Amagai, K1
Chin, K1
Niwa, Y1
Tsuji, A1
Imamura, H1
Tsuda, M1
Yasui, H2
Fujii, H1
Yamaguchi, K1
Hironaka, S1
Shimada, K1
Hyodo, I1
Ohue, M1
Hamaguchi, T1
Sakai, D1
Noura, S1
Kinugasa, Y1
Fujita, S1
Shimada, Y1
Saito, N1
Moriya, Y1
Tang, Y1
Wang, W1
Teng, XZ1
Shi, L1
Chisaki, Y1
Noda, S1
Hira, D1
Morita, SY1
Yano, Y1
Terada, T1
Tanaka, H1
Mitsunaga, S1
Kobayashi, M1
Funazaki, H1
Katayama, S1
Kuwahara, A1
Okuyama, H1
Takahashi, H1
Ohno, I1
Shimizu, S1
Sakamoto, Y1
Kondo, S1
Ueno, H1
Ochiai, A1
Suzuki, S1
Honda, K1
Yamazaki, K1
Ishikawa, K1
Oyama, K2
Fushida, S2
Kaji, M2
Takeda, T2
Yabushita, K2
Nezuka, H1
Kinami, S2
Kadoya, N1
Takai, Y2
Tsukioka, Y1
Ohyama, S1
Tsuji, K1
Tsukada, T2
Kinoshita, J2
Fujimura, T2
Ohta, T2
Kasai, T1
Nakamura, Y1
Fukuda, M1
Kitazaki, T1
Nagashima, S1
Takatani, H1
Nakano, H1
Nakatomi, K1
Ikeda, T1
Tsukamoto, K1
Oka, M1
Kohno, S1
Arima, S1
Okamoto, T1
Toki, M1
Suzuki, Y1
Naruge, D1
Kawai, K1
Kobayashi, T1
Kasuga, A1
Kitamura, H1
Takasu, A1
Nagashima, F1
Sugiyama, M1
Wang, R1
Lu, P1
Zhao, YF1
Lu, TY1
Han, JW1
Wang, JS1
Luo, SX1
Lu, SP1
Wang, GJ1
Geng, L1
Zhang, MZ1
Ma, ZY1
Song, M1
Wu, XA1
Chen, XB1
Jiao, ZM1
Wang, RL1
Park, I1
Lee, JL2
Ryu, MH1
Chang, HM1
Kim, TW2
Sym, SJ1
Lee, SS1
Jang, G1
Yoo, C1
Bae, KS1
Kang, YK1
Hong, YS1
Park, JH1
Kim, JH1
Yoon, SN1
Lim, SB1
Yu, CS1
Kim, MJ1
Jang, SJ1
Lee, JS1
Kim, JC1
Zhu, QC1
Jin, ZM1
Hirono, Y1
Yoshimoto, K1
Hirosawa, H1
Nakano, T1
Kimura, H1
Yasui, T1
Tsuneda, A1
Feliu, J4
Vicent, JM1
García-Girón, C2
Constela, M1
Fonseca, E1
Aparicio, J1
Lomas, M1
Antón-Aparicio, L1
Dorta, FJ1
Gonzalez-Baron, M2
Bedikian, AY1
Bodey, GP2
Valdivieso, M2
Burgess, MA2
Ansfield, FJ1
Kallas, GJ1
Singson, JP1
Taguchi, T2
Sato, A1
Hasegawa, K2
Kurihara, M2
Takahashi, M1
Akazawa, S1
Fukuyama, Y1
Hayakawa, M1
Sasai, T1
Kimura, K1
Hayashida, S1
Hirasawa, T1
Uchiyama, K1
Mitsui, H1
Nasu, T1
Shinohara, Y1
Sanchiz, F1
Milla, A1
Shinoda, M1
Morise, K1
Kusugami, K2
Iwase, H2
Ina, K1
Kaneko, H1
Horiuchi, Y2
Kuroiwa, A1
Suga, S3
Oka, Y1
Daniels, M1
Díaz-Rubio, E1
Guillem, V1
Montero, JM1
García-Conde, J1
Estapé, J1
Martín, M1
Herranz, C1
Ordoñez, A3
Galán, A1
Espinosa, E3
de Castro, J2
Zamora, P2
Gomez-Navarro, J2
Espinosa, J2
Vilches, Y1
de la Gandara, I2
Kim, YH1
Cheong, SK1
Lee, JD1
Park, JS1
Shin, SW1
Kim, JS1
González Barón, M2
García-Alfonso, P1
Belón, J1
Blanco, E1
Garrido, P1
Shimada, M1
Nishio, Y1
Ichihara, T1
Ichihara, S1
Saito, H1
García Girón, C1
Colmenarejo, A1
Jalón, JI1
Fernández, Y1
Kurokawa, H1
Miura, K1
Yamashita, Y1
Tokudome, S1
Murata, T1
Kajiyama, M1
Ichinose, Y1
Yano, T1
Kudoh, S1
Yoshimori, K1
Morikawa, T1
Kuba, M1
Niitani, H2
Shirasaka, T1
Shimamoto, Y1
Kato, T1
Fukushima, M1
Horikoshi, N1
Aiba, K1
Kanamaru, R1
Takeda, S1
Furue, H1
Ogawa, M1
Abe, T1
Muggia, FM1
Wu, X1
Spicer, D1
Groshen, S1
Jeffers, S1
Leichman, CG1
Leichman, L1
Chan, KK1
DeMario, MD1
Ratain, MJ1
Vogelzang, NJ1
Mani, S1
Vokes, EE1
Fleming, GF1
Melton, K1
Johnson, S1
Benner, S1
Lebwohl, D1
Hortobagyi, GN1
Blumenschein, GR1
Tashima, CK1
Buzdar, AU1
Livingston, RB1
Gutterman, JU1
Hersh, EM1
Sakata, Y1
Chiba, Y1
Kimura, M1
Fukushi, G1
Matsukawa, M1
Aoyama, H1
Sawada, Y1
Fukushi, M1
Ohyama, M2
Matsumura, M2
Katsuta, K2
Nobori, T2
Matsuyama, H1
Fukami, K1
Kiyota, R1
Yano, H1
Shima, T1
Ogawa, K1
Nagai, H1
Kyokane, K1
Miwa, Y1
Aoki, Y1
Yasue, K1
Noro, T1
Kamikawa, R1
Ninomiya, E1
Kikuchi, K1
Wakui, A1
Niijima, T1
Aso, Y1
Akaza, H1
Kameyama, S1
Koiso, K1
Kawamura, T1
Isurugi, K1
Yokoyama, M1
Shoji, F1
Furuta, S1
Matsunaga, S1
Uchizono, A1
Hanada, T1
Moriyama, I1
Kamachi, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer[NCT05919095]Phase 237 participants (Anticipated)Interventional2023-06-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for tegafur and Vomiting

ArticleYear
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor

1998

Trials

28 trials available for tegafur and Vomiting

ArticleYear
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo

2019
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2017
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2017, Jun-23, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations;

2017
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
    Cancer science, 2019, Volume: 110, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons

2019
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A

2015
Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-

2014
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr

2016
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co

2017
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat

2010
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2011
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo

2011
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
    British journal of cancer, 2004, Nov-15, Volume: 91, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ad

2004
[Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. UFTP Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug A

1995
[The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:5

    Topics: Aged; Angiotensin II; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Chil

1995
Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer.
    Japanese journal of clinical oncology, 1994, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; L

1994
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi

1995
Phase II trial of UFT activity in pretreated breast cancer patients.
    Japanese journal of clinical oncology, 1993, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; A

1993
Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non-small-cell lung cancer.
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Abdominal Pain; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1996
Phase II trial of Oral UFT and leucovorin in advanced gastric carcinoma.
    American journal of clinical oncology, 1996, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineop

1996
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Cancer, 1996, Jul-15, Volume: 78, Issue:2

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast

1996
Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin.
    Internal medicine (Tokyo, Japan), 1996, Volume: 35, Issue:12

    Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

1996
[Evaluation of neo-adjuvant chemotherapy for oral squamous cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;

1997
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cispla

1997
[Phase I study of orally administered UFT plus l-leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc

1998
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor

1996
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
    Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1999
[Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Proto

1992
[Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:11

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1990

Other Studies

18 other studies available for tegafur and Vomiting

ArticleYear
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
    Pancreas, 2021, 08-01, Volume: 50, Issue:7

    Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug C

2021
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
    British journal of cancer, 2017, Jun-06, Volume: 116, Issue:12

    Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2017
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:7

    Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histami

2014
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointest

2015
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
    Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot

2015
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    International journal of clinical oncology, 2016, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci

2016
[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Journal of gastroenterology, 2013, Volume: 48, Issue:11

    Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci

2013
Phase I evaluation of oral tegafur.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio

1983
Phase I-II studies of oral tegafur (ftorafur).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:2

    Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship,

1983
[UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina

1984
Review of a new antimetabolic agent, 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1).
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1980, Volume: 70

    Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Delayed-Action Preparations; Dogs; Drug Evalu

1980
Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
    Cancer, 1997, May-15, Volume: 79, Issue:10

    Topics: Administration, Oral; Aged; Aged, 80 and over; Ambulatory Care; Antidotes; Antimetabolites, Antineop

1997
Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer.
    Cancer, 1979, Volume: 44, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Body Weight; Breast Neoplasms; Central Nervous Syst

1979
[A comparative study of UFT enteric-coated granules with UFT capsules on the occurrence of side effects in patients with head and neck cancers--a special attention to the upper gastrointestinal tract disorders].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capsules; Diarrhea;

1990
[Treatment of nausea and vomiting induced by a 24-hour i.v. infusion of cisplatin].
    Gan no rinsho. Japan journal of cancer clinics, 1990, Volume: 36, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Therapy, Combination;

1990
[Collaborative study of UFT in far-advanced renal cell carcinoma. Urological Cooperative UFT Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug A

1988
[A phase II study of Futraful suppository in head and neck cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:7

    Topics: Aged; Anorexia; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Evaluation; Female;

1988